These trials completed more than 12 months ago and should have reported results. Some have, some have not.

These trials are not yet due to report results: some are ongoing, some completed within the past 12 months.

These trials have problematic data on the registry. Details why »

Status Trial ID Title Completion date Category
Not reported 2004-001738-17 Evaluation of the intensification of post-remissional therapy in the treatment of high-risks adult Acute Lymphoblastic Leukemia and monitoring of the minimal residual disease Ruolo della intensific... 2014-04-02 due-trials
Completed, but no date 2004-001739-53 Therapy with Alemtuzumab (Mabcampath) in patients with acute Lymphoblastic leukemia either refractoy or in relapse. Phase II, multicentric, not randomized study. bad-data
Completed, but no date Terminated 2004-002935-23 Phase II study of PS341 VELCADE in myelodysplastic syndromes MDS. bad-data
Completed, but no date, and reported results 2005-001347-37 Gemtuzumab ozogamicin (GO) combined with standard intensive chemotherapy versus standard intensive chemotherapy alone for induction/consolidation in patients 61-75 years old with previously untreate... bad-data
Completed, but no date 2005-002156-17 ''Geriatric assessment adapted'' therapy for the treatment of Ph-negative Acute lymphoblastic Leukemia in elder patients. Terapia ''geriatric assessment adapted'' per il trattamento della Leucemia ... bad-data
Completed, but no date 2005-002476-15 Phase II pilot trial to evaluate the efficacy and safety of a first-line combined therapeutic approach for young (> = 60 years old) CLL patients with advanced and progressive disease stratified... bad-data
Completed, but no date 2005-004811-31 An open label, phase II, non randomized, clinical trial of chemotherapy treatment with 5-Azacytidine plus valproic acid and eventually atra for patients diagnosed with Intermediate II and high risk My... bad-data
Completed, but no date 2005-005107-42 A Phase II Multicenter Study on the Treatment of Adult de novo Philadelphia Chromosome Positive Ph Acute Lymphoblastic Leukemia ALL with the Protein Tyrosine Kinase Inhibitor BMS-354825. bad-data
Completed, but no date 2006-006147-31 An open multicenter clinical trial to evaluate the safety, tolerability and efficacy of Deferasirox (ICL670) in patients affected by Myelodysplastic syndrome and transfusional chronic hemosiderosis. bad-data
Not reported 2006-006188-22 A randomised phase III study to compare arsenic trioxide (ATO) combined to ATRA versus standard ATRA and anthracycline-based chemotherapy (AIDA regimen) for newly diagnosed, non high-risk acute promye... 2018-11-01 due-trials
Ongoing 2007-000597-22 The protein tyrosine kinase inhibitor nilotinib as first-line treatment of Ph+ chronic myeloid leucemia (CML) in early chronic phase: a Phase II exploratory, multicenter study The protein tyrosine ... not-yet-due
Completed, but no date 2007-005374-31 An open label phase II trial of Clofarabine and Temsirolimus in older patients with relapsed or refractory Acute Myeloid Leukemia (AML) bad-data
Completed, but no date Terminated 2007-006694-91 A large-scale trial testing the intensity of CYTOreductive therapy to prevent cardiovascular events In patients with Polycythemia Vera (PV) – CYTO-PV. bad-data
Ongoing 2008-000417-30 Randomized study for the treatment of primary Immune Thrombocytopenic Purpura (ITP) in newly diagnosed untreated adult patients. Comparison of standard dose prednisone versus high-dose Dexamethasone... not-yet-due
Completed, but no date 2008-004384-19 Front-line treatment of Philadelphia positive (Ph pos), BCR-ABL positive, chronic myeloid leukemia (CML) with two tyrosine kinase inhibitors (TKI) (Nilotinib and Imatinib). A phase II exploratory mult... bad-data
Completed, but no date 2009-013271-22 Front-line treatment of Ph positive (Ph+)/Bcr-Abl positive Acute Lymphoblastic Leukemia (ALL) with two tyrosine kinase inhibitors (TKI) (Imatinib and Nilotinib). A phase II exploratory multicentric ... bad-data
Completed, but no date 2009-016075-30 Therapy of the Young Adult Acute Lymphoblastic Leukemia (ALL): treatment intensification of the pediatric protocol AIEOP LLA-2000 bad-data
Completed, but no date 2009-017663-42 A Single-Arm Multi-Center Trial of Bendamustine given with Ofatumumab (BendOfa) in Patients With Refractory or Relapsed Chronic Lymphocytic Leukemia (CLL) Studio multicentrico, a braccio singolo, d... bad-data
Ongoing 2010-019119-39 A multicenter Total Therapy Strategy for De Novo Adult Philadelphia Chromosome Positive (Ph+) Acute Lymphoblastic Leukemia (ALL) Patients Studio multicentrico per una strategia terapeutica comple... not-yet-due
Completed, but no date 2010-019742-12 A Phase II study with a sequential clofarabine-cyclophosphamide combination schedule as salvage therapy for refractory and relapsed acute lymphoblastic leukemia (ALL) in adult patients Studio di ... bad-data
Completed, but no date 2010-023809-36 Risk-adapted, MRD-directed therapy for young adults with newly diagnosed acute myeloid leukemia. Risk-adapted, MRD-directed therapy for young adults with newly diagnosed acute myeloid leukemia. bad-data
Not reported 2011-002787-25 The protein tyrosine kinase inhibitor nilotinib as first-line treatment of Ph+, BCR-ABL+ chronic myeloid leukemia (CML) in early chronic phase: a phase IIIb, multicenter study of complete molecular re... 2017-11-30 due-trials
Completed, but no date 2011-004608-39 Eltrombopag in patients with delayed post transplant thrombocytopenia Eltrombopag in pazienti con trombocitopenia ritardata post-trapianto bad-data
Ongoing 2011-005329-27 Phase 2 multicenter study to assess the efficacy and the safety of front-line Fludarabine, Cyclophosphamide and Ofatumumab (FCO2) chemoimmunotherapy in young (≤65 yrs) patients with Chronic Lymphocyti... not-yet-due
Completed, but no date 2011-006329-42 Short course of Bortezomib in anemic patients with refractory cold agglutinin disease Ciclo breve di Bortezomib in pazienti anemici con crioagglutinemia refrattaria bad-data
Other 2012-002761-35 Trattamento di prima linea della Leucemia Linfoblastica Acuta (LLA) Philadelphia positiva (Ph+)/BCR/ABL+ con un nuovo potente inibitore delle Tirosin-chinasi (TKI), AP24534 (Ponatinib). Studio multice... not-yet-due
Ongoing 2014-000383-18 National Treatment Program of Philadelphia Chromosome-negative Adult Acute Lymphoblastic Leukemia with Pegylated Asparaginase Added to a Lineage-Targeted Risk- and Minimal Residual Disease-Oriented St... not-yet-due
Ongoing 2014-002714-23 A phase 2 multicenter study to assess the activity and the safety of front-line Ibrutinib plus Rituximab (IR) in unfit patients with Chronic Lymphocytic Leukemia (CLL). Studio multicentrico di ... not-yet-due
Ongoing 2015-000684-13 A Phase II study of the combination of Ofatumumab and Ibrutinib followed by allogeneic bone marrow transplant or consolidation for pretreated high risk patients with Chronic Lymphocytic Leukemia ... not-yet-due
Ongoing 2015-001102-34 Optimizing Ponatinib USe (OPUS). Studio GIMEMA di fase 2 sull¿efficacia e sul profilo di rischio di ponatinib, 30 mg al giorno, in pazienti con Leucemia Mieloide Cronica (LMC) in Fase Cronica, resiste... not-yet-due
Completed, but no date 2015-001327-23 Eltrombopag as Second line Therapy in adult patients with primary Immune Thrombocytopenia (ESTIT study) in an attempt to achieve long-term remission: a single arm multicenter phase II clinical and bio... bad-data
Ongoing 2015-005248-33 SUSTRENIM Study – GIMEMA CML1415 Sustained treatment-free remission in BCR-ABL+ chronic myeloid leukemia: a prospective study comparing Nilotinib versus Imatinib with switch to Nilotinib in absence of... not-yet-due
Completed, but no date 2016-001083-11 D-ALBA Front-Line Sequential Treatment of Adult Philadelphia Chromosome Positive (Ph+) Acute Lymphoblastic Leukemia (ALL) Patients with Dasatinib and the Bispecific Monoclonal Antibody Blinatumomab ... bad-data
Ongoing 2017-004251-23 National Treatment Program with Sequential Chemotherapy and Blinatumomab to Improve Minimal Residual Disease Response and Survival in Philadelphia Chromosome-Negative B-Cell Programma terapeutico ... not-yet-due
Exempt 2018-000392-33 A Safety Run-in and phase II, open-label, multicentre, study investigating safety, tolerability and effectiveness of Venetoclax add in combination at Fludarabine, Cytarabine and Idarubicine in induct... not-yet-due
Ongoing 2018-000877-61 Activity and safety of front-line venetoclax and rituximab association (VeRiTAs) in young and fit patients with chronic lymphocytic leukemia (CLL) and unmutated IGHV and/or disrupted TP53. A phase 2 m... not-yet-due
Ongoing 2018-003006-32 "A Phase IIA Study of Feasibility and Effectiveness of Inotuzumab Ozogamicin (IO) in Adult Patients with B-Cell Acute Lymphoblastic Leukemia with positive Minimal Residual Disease before any Hematopoi... not-yet-due
Completed, but no date Terminated 2018-003517-17 Asparaginase Activity Monitoring (AAM) in adult patients with Acute Lymphoblastic Leukemia (ALL). Monitoraggio dell’Attività dell’Asparaginasi (AAM) in pazienti adulti con Leucemia Linfoblastica Ac... bad-data
Ongoing 2019-000159-14 Prospective study on the incidence of hepatitis B virus reactivation in untreated patients with diffuse Large B-Cell Lymphoma/Chronic Lymphoid Leukemia HBsAg-positive treated with Rituximab, Chemother... not-yet-due
Ongoing 2019-003871-20 Phase III study to assess the impact of gemtuzumab ozogamicin, in combination with standard chemotherapy, on the levels of minimal residual disease, and the role of glasdegib as a post-transplant main... not-yet-due
Ongoing 2019-003936-21 A Phase 3, prospective, randomized multi-center intervention trial of early intensification in AML patients bearing FLT3 mutations based on peripheral blast clearance. A MYNERVA-GIMEMA study. AMELIOR... not-yet-due
Ongoing 2019-003997-25 Prospective randomized study on the feasibility of allogeneic stem cell transplantation in higher-risk-myelodysplastic syndromes, performed upfront or preceded by azacitidine or conventional chemother... not-yet-due
Ongoing 2020-001543-94 Tagraxofusp in Patients with CD123+ or with Blastic Plasmacytoid Dendritic Cell Neoplasm Immunophenotype-like Acute Myeloid Leukemia. Tagraxofusp nei pazienti affetti da Leucemia Mieloide Acuta CD1... not-yet-due
Ongoing 2020-003912-28 Ponatinib for the management of minimal residual disease (MRD) and hematologic relapse in adult Ph+ acute lymphoblastic leukemia (Ph+ ALL) patients. Ponatinib per la gestione della Malattia Minima ... not-yet-due
Ongoing 2020-006048-15 Newly Diagnosed Adult Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia (Ph+ ALL). Sequential Treatment with Ponatinib and the Bispecific Monoclonal Antibody Blinatumomab vs Chemotherapy a... not-yet-due
Ongoing 2020-006114-20 A Phase 2, prospective, multi-center intervention trial in patients with acute myeloid leukemia secondary to myeloproliferative neoplasms unfit for intensive chemotherapy investigating a treatment com... not-yet-due
Ongoing 2021-002361-17 A multicentric phase 2 study of venetoclax and azacitidine for the management of the molecular relapse/progression in adult NPM1- mutaded acute myeloid leukemia. Studio multicentrico di fase II su ... not-yet-due
Ongoing 2022-000633-17 Combination of Ponatinib Plus Chemotherapy As Frontline Treatment For Patients With BCR/ABL1-Like Acute Lymphoblastic Leukemia (BCR/ABL1-Like ALL) - BALLik Combinazione di ponatinib e chemioterapia... not-yet-due
Ongoing 2022-002579-12 Front-Line Venetoclax and Obinutuzumab combination followed by Venetoclax or Venetoclax and Zanubrutinib combination in patients with residual disease: a minimal residual disease (MRD) tailored treatm... not-yet-due